Hydrodynamic coefficients of mussel dropper lines derived from large-scale experiments and structural dynamics

The expansion of marine aquaculture production is driven by a high market demand for marine proteins and a stagnation of wild catch of fish. Bivalve farming, i.e., the cultivation of oysters, mussels and scallops, is an important part of the ongoing market dynamics and production expansion. As marine spatial planning is considering various use purposes, available space for near-shore aquaculture is already becoming scarce; this has fueled research and development initiatives to enable production installations further offshore. The highly energetic conditions at more exposed offshore marine sites lead to increased loads on aquaculture systems and their components and it is still not sufficiently understood how the load transfer from oceanic environmental conditions onto shellfish-encrusted surfaces attached to elastic ropes may be appropriately quantified. This study data gathered large-scale data sets in a wave tank facility, which are used to validate a novel, numerical model, building on the dynamics of rope structures which allows for the determination of the hydrodynamic loads transferred to the dropper lines. The forces and hydrodynamic parameters are measured and numerically analyzed. Based on the results, drag and inertia coefficients are determined. A drag coefficient of CD= 1.1 and an inertia coefficient of CM= 1.7 are recommended to model shellfish-encrusted dropper lines exposed to oscillatory flows with KC = 40–90. The numerical model for the determination of wave-induced forces on mussel dropper lines is developed and validated using the experimental data. It employs a modified Morison equation, which takes into account the displacement of the mussel dropper line. The influence of varying aquaculture-related parameters is discussed by applying the numerical model. Based on the gathered insights, recommendations can be given from an engineering point of view concerning the optimal placement of mussel aquaculture within the water column

Large-scale laboratory experiments on mussel dropper lines in ocean surface waves

The rapid growth of marine aquaculture around the world accentuates issues of sustainabil-ity and environmental impacts of large-scale farming systems. One potential mitigation strategy is to relocate to more energetic offshore locations. However, research regarding the forces which waves and currents impose on aquaculture structures in such conditions is still scarce. The present study aimed at extending the knowledge related to live blue mussels (Mytilus edulis), cultivated on dropper lines, by unique, large-scale laboratory experiments in the Large Wave Flume of the Coastal Research Center in Hannover, Germany. Nine-months-old live dropper lines and a surrogate of 2.0 m length each are exposed to regular waves with wave heights between 0.2 and 1.0 m and periods between 1.5 and 8.0 s. Force time histories are recorded to investigate the inertia and drag characteristics of live mussel and surrogate dropper lines. The surrogate dropper line was developed from 3D scans of blue mussel dropper lines, using the surface descriptor Abbott–Firestone Curve as quality parameter. Pull-off tests of individual mussels are conducted that reveal maximum attachment strength ranges of 0.48 to 10.55 N for mussels that had medium 3.04 cm length, 1.60 cm height and 1.25 cm width. Mean drag coefficients of CD = 3.9 were found for live blue mussel lines and CD = 3.4 for the surrogate model, for conditions of Keulegan–Carpenter number (KC) 10 to 380, using regular wave tests. © 2020 by the authors. Licensee MDPI, Basel, Switzerland

Toll-Like Receptor 2-Deficient Mice Are Highly Susceptible to Streptococcus pneumoniae Meningitis because of Reduced Bacterial Clearing and Enhanced Inflammation

Toll-like receptor-2 (TLR2) mediates host responses to gram-positive bacterial wall components. TLR2 function was investigated in a murine Streptococcus pneumoniae meningitis model in wild-type (wt) and TLR2-deficient (TLR2−/−) mice. TLR2−/− mice showed earlier time of death than wt mice (P<.02). Plasma interleukin-6 levels and bacterial numbers in blood and peripheral organs were similar for both strains. With ceftriaxone therapy, none of the wt but 27% of the TLR2−/− mice died (P<.04). Beyond 3 hours after infection, TLR2−/− mice had higher bacterial loads in brain than did wt mice, as assessed with luciferase-tagged S. pneumoniae by means of a Xenogen-CCD (charge-coupled device) camera. After 24 h, tumor necrosis factor activity was higher in cerebrospinal fluid of TLR2−/− than wt mice (P<.05) and was related to increased blood-brain barrier permeability (Evans blue staining, P<.02). In conclusion, the lack of TLR2 was associated with earlier death from meningitis, which was not due to sepsis but to reduced brain bacterial clearing, followed by increased intrathecal inflammatio

Contract nonperformance risk and uncertainty in insurance markets

Insurance contracts may fail to perform, leading to a default on valid claims. We relax the standard assumption of known probabilities for such defaults by allowing for uncertainty. Within a large behavioral experiment, we show that introducing risk and uncertainty each leads to significant reductions in insurance demand and that the effects are comparable in magnitude (17.1 and 14.5 percentage points). Furthermore, risk- and ambiguity-averse participants are affected most. These findings are in line with models incorporating ambiguity attitudes or, alternatively, pessimistic beliefs. An analysis of the belief and decision dynamics suggests persistent pessimistic priors and disregard of peer experiences, leading to a stable uncertainty effect

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

BACKGROUND The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting. METHODS An interim analysis was conducted after all patients completed 6 months of erenumab treatment. Patients kept a headache diary and completed questionnaires at follow up visits. The overall study duration comprises 24 months. RESULTS In total, 172 adults with chronic or episodic migraine from 19 different sites across Switzerland were enrolled to receive erenumab every 4 weeks. At baseline, patients had 16.6 ± 7.2 monthly migraine days (MMD) and 11.6 ± 7.0 acute migraine-specific medication days per month. After 6 months, erenumab treatment reduced Headache Impact Test (HIT-6™) scores by 7.7 ± 8.4 (p < 0.001), the modified Migraine Disability Assessment (mMIDAS) by 14.1 ± 17.8 (p < 0.001), MMD by 7.6 ± 7.0 (p < 0.001) and acute migraine-specific medication days per month by 6.6 ± 5.4 (p < 0.001). Erenumab also reduced the impact of migraine on social and family life, as evidenced by a reduction of Impact of Migraine on Partners and Adolescent Children (IMPAC) scores by 6.1 ± 6.7 (p < 0.001). Patients reported a mean effectiveness of 67.1, convenience of 82.4 and global satisfaction of 72.4 in the Treatment Satisfaction Questionnaire for Medication (TSQM-9). In total, 99 adverse events (AE) and 12 serious adverse events (SAE) were observed in 62 and 11 patients, respectively. All SAE were regarded as not related to the study medication. CONCLUSIONS Overall quality of life improved and treatment satisfaction was rated high with erenumab treatment in real-world clinical practice. In addition, the reported impact of migraine on spouses and children of patients was reduced. TRIAL REGISTRATION BASEC ID 2018-02,375 in the Register of All Projects in Switzerland (RAPS)

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

BACKGROUND The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting. METHODS An interim analysis was conducted after all patients completed 6 months of erenumab treatment. Patients kept a headache diary and completed questionnaires at follow up visits. The overall study duration comprises 24 months. RESULTS In total, 172 adults with chronic or episodic migraine from 19 different sites across Switzerland were enrolled to receive erenumab every 4 weeks. At baseline, patients had 16.6 ± 7.2 monthly migraine days (MMD) and 11.6 ± 7.0 acute migraine-specific medication days per month. After 6 months, erenumab treatment reduced Headache Impact Test (HIT-6™) scores by 7.7 ± 8.4 (p < 0.001), the modified Migraine Disability Assessment (mMIDAS) by 14.1 ± 17.8 (p < 0.001), MMD by 7.6 ± 7.0 (p < 0.001) and acute migraine-specific medication days per month by 6.6 ± 5.4 (p < 0.001). Erenumab also reduced the impact of migraine on social and family life, as evidenced by a reduction of Impact of Migraine on Partners and Adolescent Children (IMPAC) scores by 6.1 ± 6.7 (p < 0.001). Patients reported a mean effectiveness of 67.1, convenience of 82.4 and global satisfaction of 72.4 in the Treatment Satisfaction Questionnaire for Medication (TSQM-9). In total, 99 adverse events (AE) and 12 serious adverse events (SAE) were observed in 62 and 11 patients, respectively. All SAE were regarded as not related to the study medication. CONCLUSIONS Overall quality of life improved and treatment satisfaction was rated high with erenumab treatment in real-world clinical practice. In addition, the reported impact of migraine on spouses and children of patients was reduced. TRIAL REGISTRATION BASEC ID 2018-02,375 in the Register of All Projects in Switzerland (RAPS)

Advances in crop insect modelling methods—Towards a whole system approach

A wide range of insects affect crop production and cause considerable yield losses. Difficulties reside on the development and adaptation of adequate strategies to predict insect pests for their timely management to ensure enhanced agricultural production. Several conceptual modelling frameworks have been proposed, and the choice of an approach depends largely on the objective of the model and the availability of data. This paper presents a summary of decades of advances in insect population dynamics, phenology models, distribution and risk mapping. Existing challenges on the modelling of insects are listed; followed by innovations in the field. New approaches include artificial neural networks, cellular automata (CA) coupled with fuzzy logic (FL), fractal, multi-fractal, percolation, synchronization and individual/agent based approaches. A concept for assessing climate change impacts and providing adaptation options for agricultural pest management independently of the United Nations Intergovernmental Panel on Climate Change (IPCC) emission scenarios is suggested. A framework for estimating losses and optimizing yields within crop production system is proposed and a summary on modelling the economic impact of pests control is presented. The assessment shows that the majority of known insect modelling approaches are not holistic; they only concentrate on a single component of the system, i.e. the pest, rather than the whole crop production system. We suggest system thinking as a possible approach for linking crop, pest, and environmental conditions to provide a more comprehensive assessment of agricultural crop production.Peer reviewe

Epigenetics in atherosclerosis and inflammation

Introduction Epigenetics explained Epigenetic alterations are reversible Atherosclerosis Epigenetics and association with atherosclerosis Epigenetic regulation of cell activity T cells Monocytes Endothelial cells Smooth muscle cells Chemokines, their receptors and other genes involved in inflammation eNOS iNOS CCL11 (eotaxin) CCR5 Epigenetics in (vascular) inflammation KDM6B Oestrogen receptor COX2 Transcriptional regulation of MHC molecules - the role of CIITA Non-histone targets MicroRNAs Conclusions Atherosclerosis is a multifactorial disease with a severe burden on western society. Recent insights into the pathogenesis of atherosclerosis underscore the importance of chronic inflammation in both the initiation and progression of vascular remodelling. Expression of immunoregulatory molecules by vascular wall components within the atherosclerotic lesions is accordingly thought to contribute to the ongoing inflammatory process. Besides gene regulatory proteins (transcription factors), epigenetic mechanisms also play an essential and fundamental role in the transcriptional control of gene expression. These epigenetic mechanisms change the accessibility of chromatin by DNA methylation and histone modifications. Epigenetic modulators are thus critically involved in the regulation of vascular, immune and tissue-specific gene expression within the atherosclerotic lesion. Importantly, epigenetic processes are reversible and may provide an excellent therapeutic target. The concept of epigenetic regulation is gradually being recognized as an important factor in the pathogenesis of atherosclerosis. Recent research provides an essential link between inflammation and reprogramming of the epigenome. In this review we therefore discuss the basis of epigenetic regulation - and the contribution thereof in the regulation of inflammatory processes in general and during atherosclerosis in particular. Moreover we highlight potential therapeutic interventions based on epigenetic mechanisms.Stemcel biology/Regenerative medicine (incl. bloodtransfusion